Literature DB >> 19337745

The effects of sildenafil and acetazolamide on breathing efficiency and ventilatory control during hypoxic exercise.

Sophie Lalande1, Eric M Snyder, Thomas P Olson, Minelle L Hulsebus, Marek Orban, Virend K Somers, Bruce D Johnson, Robert P Frantz.   

Abstract

The reduced arterial oxygen tension at high altitude impairs the ability to work. Acetazolamide improves arterial oxygen saturation (SaO(2)) by increasing ventilation but is associated with an increased work and cost of breathing. Depending on the settings, sildenafil can also increases SaO(2) possibly through a reduction in pulmonary hypertension and interstitial edema, which could improve ventilation-perfusion matching. The objective of this study is to determine the effects of acetazolamide and sildenafil on ventilatory control and breathing efficiency (V(E)/VCO(2)) during submaximal steady-state hypoxic exercise in healthy individuals. Following 18 h of hypoxic exposure in an altitude tent at an oxygen concentration of 12.5% (simulated altitude of 4,300 m), 15 participants performed 10 min of hypoxic exercise on a stationary bicycle at 40% of their sea level peak oxygen uptake (VO(2)) while randomly receiving sildenafil 40 mg (SIL), acetazolamide 125 mg (ACZ) or a placebo (PLA). There was no difference in VO(2) during exercise between conditions while SaO(2) was greater with acetazolamide compared to both placebo and sildenafil. Acetazolamide increased ventilation (PLA 49.0 +/- 3.2, SIL 47.7 +/- 3.1, ACZ 52.1 +/- 3.0 l/min) and reduced end-tidal CO(2) (P(ET)CO(2)) (PLA 32.1 +/- 0.8, SIL 32.8 +/- 0.9, ACZ 29.2 +/- 0.7 mmHg) compared to placebo and sildenafil. Breathing was less efficient with acetazolamide (increased V(E)/VCO(2)) in comparison to placebo and sildenafil (PLA 41.5 +/- 1.0, SIL 40.4 +/- 1.3, ACZ 45.4 +/- 1.0) while sildenafil did not change V(E)/VCO(2) during hypoxic exercise. In conclusion, acetazolamide increased ventilation and reduced breathing efficiency while sildenafil did not affect breathing efficiency despite a trend toward a blunted ventilatory response, possibly due to a reduction in pulmonary hypertension and/or ventilatory drive, during submaximal hypoxic exercise in healthy individuals.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19337745      PMCID: PMC2732568          DOI: 10.1007/s00421-009-1042-5

Source DB:  PubMed          Journal:  Eur J Appl Physiol        ISSN: 1439-6319            Impact factor:   3.078


  33 in total

1.  Ventilatory efficiency during exercise in healthy subjects.

Authors:  Xing-Guo Sun; James E Hansen; Nuria Garatachea; Thomas W Storer; Karlman Wasserman
Journal:  Am J Respir Crit Care Med       Date:  2002-12-01       Impact factor: 21.405

2.  Observations on the composition of alveolar air on everest, 1933.

Authors:  R Greene
Journal:  J Physiol       Date:  1934-11-12       Impact factor: 5.182

3.  Man's respiratory response during acclimatization to high altitude.

Authors:  H RAHN; A B OTIS
Journal:  Fed Proc       Date:  1948-03

4.  Sildenafil improves exercise hemodynamics and oxygen uptake in patients with systolic heart failure.

Authors:  Gregory D Lewis; Justine Lachmann; Janice Camuso; John J Lepore; Jordan Shin; Maryann E Martinovic; David M Systrom; Kenneth D Bloch; Marc J Semigran
Journal:  Circulation       Date:  2006-12-18       Impact factor: 29.690

5.  Sildenafil improves cardiac output and exercise performance during acute hypoxia, but not normoxia.

Authors:  Andrew R Hsu; Kimberly E Barnholt; Nicolas K Grundmann; Joseph H Lin; Stewart W McCallum; Anne L Friedlander
Journal:  J Appl Physiol (1985)       Date:  2006-02-02

6.  Sildenafil inhibits altitude-induced hypoxemia and pulmonary hypertension.

Authors:  Jean-Paul Richalet; Pierre Gratadour; Paul Robach; Isabelle Pham; Michèle Déchaux; Aude Joncquiert-Latarjet; Pascal Mollard; Julien Brugniaux; Jérémy Cornolo
Journal:  Am J Respir Crit Care Med       Date:  2004-10-29       Impact factor: 21.405

7.  Nitric oxide/cGMP protects endothelial cells from hypoxia-mediated leakiness.

Authors:  Gopi Krishna Kolluru; K P Tamilarasan; Arun Stephen Rajkumar; S Geetha Priya; Megha Rajaram; Niyas K Saleem; Syamantak Majumder; B M Jaffar Ali; G Illavazagan; Suvro Chatterjee
Journal:  Eur J Cell Biol       Date:  2007-11-26       Impact factor: 4.492

8.  Effects of sildenafil on exercise capacity in hypoxic normal subjects.

Authors:  Vitalie Faoro; Michel Lamotte; Gael Deboeck; Adriana Pavelescu; Sandrine Huez; Hervé Guenard; Jean-Benoît Martinot; Robert Naeije
Journal:  High Alt Med Biol       Date:  2007       Impact factor: 1.981

9.  Acetazolamide reduces exercise capacity and increases leg fatigue under hypoxic conditions.

Authors:  Luke A Garske; Michael G Brown; Stephen C Morrison
Journal:  J Appl Physiol (1985)       Date:  2002-10-04

10.  Stimulation of pulmonary vagal afferent C-fibers by lung edema in dogs.

Authors:  A M Roberts; J Bhattacharya; H D Schultz; H M Coleridge; J C Coleridge
Journal:  Circ Res       Date:  1986-04       Impact factor: 17.367

View more
  10 in total

Review 1.  New insights into carbonic anhydrase inhibition, vasodilation, and treatment of hypertensive-related diseases.

Authors:  Erik R Swenson
Journal:  Curr Hypertens Rep       Date:  2014-09       Impact factor: 5.369

Review 2.  Interventions for preventing high altitude illness: Part 1. Commonly-used classes of drugs.

Authors:  Víctor H Nieto Estrada; Daniel Molano Franco; Roger David Medina; Alejandro G Gonzalez Garay; Arturo J Martí-Carvajal; Ingrid Arevalo-Rodriguez
Journal:  Cochrane Database Syst Rev       Date:  2017-06-27

3.  Phosphodiesterase type 5 inhibitors for high-altitude pulmonary hypertension: a meta-analysis.

Authors:  Bo Jin; Xin-Ping Luo; Huan-Chun Ni; Hai-Ming Shi
Journal:  Clin Drug Investig       Date:  2010       Impact factor: 2.859

4.  Interventions for preventing high altitude illness: Part 3. Miscellaneous and non-pharmacological interventions.

Authors:  Daniel Molano Franco; Víctor H Nieto Estrada; Alejandro G Gonzalez Garay; Arturo J Martí-Carvajal; Ingrid Arevalo-Rodriguez
Journal:  Cochrane Database Syst Rev       Date:  2019-04-23

5.  Sildenafil therapy in thalassemia patients with Doppler-defined risk of pulmonary hypertension.

Authors:  Claudia R Morris; Hae-Young Kim; John Wood; John B Porter; Elizabeth S Klings; Felicia L Trachtenberg; Nancy Sweeters; Nancy F Olivieri; Janet L Kwiatkowski; Lisa Virzi; Sylvia T Singer; Ali Taher; Ellis J Neufeld; Alexis A Thompson; Vandana Sachdev; Sandra Larkin; Jung H Suh; Frans A Kuypers; Elliott P Vichinsky
Journal:  Haematologica       Date:  2013-04-12       Impact factor: 9.941

Review 6.  Interventions for preventing high altitude illness: Part 2. Less commonly-used drugs.

Authors:  Alejandro Gonzalez Garay; Daniel Molano Franco; Víctor H Nieto Estrada; Arturo J Martí-Carvajal; Ingrid Arevalo-Rodriguez
Journal:  Cochrane Database Syst Rev       Date:  2018-03-12

7.  Ventilatory oscillations at exercise: effects of hyperoxia, hypercapnia, and acetazolamide.

Authors:  Eric Hermand; François J Lhuissier; Julie Larribaut; Aurélien Pichon; Jean-Paul Richalet
Journal:  Physiol Rep       Date:  2015-06

8.  Sildenafil does not reliably improve exercise performance in hypoxia: a systematic review.

Authors:  Eric Alexander Carter; Keith Lohse; William Sheel; Michael Koehle
Journal:  BMJ Open Sport Exerc Med       Date:  2019-03-29

Review 9.  Systematic Review of the Effects of Phosphodiesterase-5 Inhibitors and Dexamethasone on High Altitude Pulmonary Edema (HAPE).

Authors:  Amy Bliss; Sonia Mahajan; Kevin M Boehm
Journal:  Spartan Med Res J       Date:  2019-03-04

10.  Side effects of acetazolamide: a systematic review and meta-analysis assessing overall risk and dose dependence.

Authors:  Christopher N Schmickl; Robert L Owens; Jeremy E Orr; Bradley A Edwards; Atul Malhotra
Journal:  BMJ Open Respir Res       Date:  2020-04
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.